Non Muscle Invasive Bladder Cancer Clinical Trials

6 recruiting

Non Muscle Invasive Bladder Cancer Trials at a Glance

6 actively recruiting trials for non muscle invasive bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Nanjing, Alexandria, and Anchorage. Lead sponsors running non muscle invasive bladder cancer studies include The First Affiliated Hospital with Nanjing Medical University, IRCCS San Raffaele, and ImmunityBio, Inc..

Browse non muscle invasive bladder cancer trials by phase

Treatments under study

About Non Muscle Invasive Bladder Cancer Clinical Trials

Looking for clinical trials for Non Muscle Invasive Bladder Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non Muscle Invasive Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non Muscle Invasive Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Not Applicable

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT07036731
Recruiting
Phase 2

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137
Recruiting
Not Applicable

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT06287541
Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder CancerBladder NeoplasmNon Muscle Invasive Bladder Cancer+8 more
IRCCS San Raffaele20,000 enrolled1 locationNCT06167356